Abbott pays $670m to settle Gill and 2,000 NEC claims, $70m above one judgment

Abbott Laboratories (NYSE: ABT) has reached agreements with three law firms to resolve the high-profile Gill case and necrotizing enterocolitis claims involving approximately 2,000 additional individuals for an aggregate amount of about US$670 million. The settlement is financially substantial, but its structure is notable because Abbott said the Gill judgment and accumulated interest alone had reached approximately US$600 million, meaning the broader package covering roughly 2,000 additional claimants costs only about US$70 million more than the amount the company faced if it simply paid that one judgment.

The Gill litigation began with a July 2024 Missouri jury verdict awarding US$495 million in damages. Abbott appealed, but after the Missouri Court of Appeals rejected the challenge, the judgment plus accumulated interest had grown to approximately US$600 million. Instead of continuing the appeal process or paying that amount solely to resolve Gill, Abbott negotiated a wider settlement with the three law firms.

The agreements do not resolve the entire litigation universe. Abbott said roughly 1,700 lawsuits remain pending in federal and state courts involving claims on behalf of approximately 12,700 infants, including some cases with disputed product identification, duplicate filings or other issues the company says could ultimately remove claims from the pool.

How significant is the $670m Abbott settlement financially?

Compared with Abbott’s recent operating scale, the settlement is meaningful but manageable. Abbott generated US$12.59 billion of second-quarter sales and US$928 million of GAAP net earnings, meaning the US$670 million settlement equals roughly 5.3% of one quarter’s revenue and about 72% of second-quarter GAAP profit.

Abbott generated US$3.80 billion of operating cash flow during the first six months of 2026. The settlement amount is equivalent to about 17.6% of that first-half operating cash generation, although the timing and accounting treatment of settlement payments may differ from a simple one-period cash comparison.

The more revealing comparison is with Gill itself. Paying US$670 million to dispose of the Gill exposure and claims involving roughly 2,000 additional people represents an aggregate settlement only around US$70 million above the approximately US$600 million Abbott said the Gill judgment and interest had reached. The economics therefore suggest the company obtained considerably broader litigation closure for an incremental amount much smaller than the headline settlement total.

That should not be interpreted as an average settlement of US$35,000 for each additional claimant because Abbott has not disclosed how the US$670 million is allocated among Gill and the other claims. The comparison simply illustrates the difference between the amount Abbott already faced in one adjudicated case and the total cost of the wider package.

Does the agreement substantially resolve Abbott’s preterm formula litigation?

It removes an important portion, but not the majority of the outstanding claimant population described by Abbott. Approximately 2,000 additional individuals are covered alongside Gill, while the company says claims involving about 12,700 infants remain pending across roughly 1,700 federal and state lawsuits.

Abbott also argues that the remaining headline number overstates the economically valid population because it includes individuals who named both Abbott and Mead Johnson without identifying which manufacturer’s formula was used, claims involving infants diagnosed with NEC before receiving formula, people never diagnosed with NEC and duplicate claims appearing in multiple jurisdictions. Those assertions are Abbott’s characterization of its litigation inventory and do not themselves determine how courts will dispose of individual cases.

The legal landscape has nevertheless shifted during 2026. Abbott prevailed in the first three federal multidistrict-litigation bellwether cases at the pretrial stage, and the U.S. Court of Appeals for the Seventh Circuit affirmed the first of those judgments in July. An Illinois appeals court also reversed a US$60 million verdict against Mead Johnson in June, while a Florida state court dismissed another preterm-formula case in March.

Abbott said the settlements represent compromises of disputed claims and do not constitute an admission of liability. The company continues to maintain that its specialty preterm formulas are safe and medically necessary, while plaintiffs in the broader litigation have alleged that cow’s-milk-based preterm formulas or fortifiers caused or contributed to NEC and that warnings were inadequate.

Why does NEC litigation remain a material risk after the settlement?

The remaining scale is the primary reason. Even after resolving claims involving approximately 2,000 individuals, Abbott still faces a reported claimant population several times larger. The financial outcome cannot be extrapolated from the current agreement because individual legal theories, jurisdictions, product identification and factual circumstances vary widely.

Abbott’s 2025 annual report had previously said it could not reasonably estimate a range of potential losses for the preterm-formula litigation and had not recorded a reserve specifically for those lawsuits at year-end because management did not then consider a material loss probable. The US$670 million settlement represents a major change from that earlier uncertainty for the group of cases now being resolved.

The company is large enough to absorb the settlement without making it an existential balance-sheet issue. Abbott’s second-quarter sales exceeded US$12.5 billion, adjusted net earnings were US$2.29 billion and first-half operating cash flow was US$3.8 billion. It also raised full-year adjusted EPS guidance in July after reporting stronger-than-expected second-quarter results.

What investors cannot yet determine is whether US$670 million represents the beginning of a broader settlement framework or a comparatively attractive resolution of one particularly expensive judgment plus a defined group of additional claims. With claims involving roughly 12,700 infants still listed as pending, the litigation overhang has been reduced but clearly not eliminated.